Department of Geriatrics, the Second People' Hospital of Wuhu, Anhui, 230032, China.
Department of Endocrinology, the Second People' Hospital of Wuhu, Anhui, 230032, China.
BMC Endocr Disord. 2023 Apr 7;23(1):79. doi: 10.1186/s12902-023-01309-2.
Numerous studies have reported the striking result that aspirin use is associated with higher bone mineral density (BMD), suggesting its potential as a population-wide osteoporosis prevention measure. Therefore, this study aimed to examine the impact of chronic low-dose aspirin use on bone remodeling biomarkers and BMD in an aging population.
Between September and November of 2019, clinical data regarding the medication use, serum bone remodeling biomarkers, and BMD of 567 consecutively hospitalized patients, a minimum of 50 years old with type 2 diabetes mellitus (T2DM), were collected. The cross-sectional associations between chronic low-dose aspirin use and serum concentrations of bone remodeling biomarkers and BMD were estimated separately using linear regression. Potential confounding variables were controlled for, including age, sex, and comorbidities.
Low-dose aspirin users had significantly lower serum bone alkaline phosphatase (BAP) concentrations than non-users (82.44 ± 28.03 U/L vs 90.71 ± 32.79 U/L, p = 0.025). On the other hand, low-dose aspirin users had insignificantly higher vertebral BMD (0.95 ± 0.19 vs 0.91 ± 0.21, p = 0.185), femoral neck BMD (0.80 ± 0.15 vs 0.78 ± 0.17, p = 0.309) and Ward's triangle BMD (0.46 ± 0.14 vs 0.44 ± 0.13, p = 0.209), regardless of adjustment.
This cross-sectional study demonstrated that chronic use of low-dose aspirin was associated with significantly lower serum concentrations of BAP in hospitalized patients with T2DM. The mechanism causing the insignificantly higher BMD observed in chronic aspirin users in this study and the significant increments in BMD reported in previous studies requires further clarification in other clinical trials.
许多研究报告称，阿司匹林的使用与更高的骨密度（BMD）有关，这表明它有可能成为一种广泛的骨质疏松症预防措施。因此，本研究旨在检查慢性低剂量阿司匹林使用对老年人群中骨重塑生物标志物和 BMD 的影响。
在 2019 年 9 月至 11 月期间，收集了 567 例连续住院的 2 型糖尿病（T2DM）患者的药物使用、血清骨重塑生物标志物和 BMD 的临床数据，这些患者的年龄均至少为 50 岁。使用线性回归分别估计慢性低剂量阿司匹林使用与血清骨重塑生物标志物和 BMD 之间的横断面关联。控制了潜在的混杂变量，包括年龄、性别和合并症。
低剂量阿司匹林使用者的血清骨碱性磷酸酶（BAP）浓度明显低于非使用者（82.44±28.03 U/L 比 90.71±32.79 U/L，p=0.025）。另一方面，低剂量阿司匹林使用者的椎体 BMD（0.95±0.19 比 0.91±0.21，p=0.185）、股骨颈 BMD（0.80±0.15 比 0.78±0.17，p=0.309）和 Ward 三角区 BMD（0.46±0.14 比 0.44±0.13，p=0.209）均有显著升高，但未调整。
这项横断面研究表明，在 2 型糖尿病住院患者中，慢性使用低剂量阿司匹林与血清 BAP 浓度显著降低有关。本研究中观察到的慢性阿司匹林使用者 BMD 升高但不显著，以及以前研究中报告的 BMD 显著增加的机制需要在其他临床试验中进一步阐明。
